{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T08:53:25Z","timestamp":1776934405858,"version":"3.51.2"},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.ygyno.2016.02.025","type":"journal-article","created":{"date-parts":[[2016,3,23]],"date-time":"2016-03-23T09:31:29Z","timestamp":1458725489000},"page":"43-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology\/Gynecologic Oncology Group study"],"prefix":"10.1016","volume":"141","author":[{"given":"Andrea P.","family":"Myers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia L.","family":"Filiaci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Pearl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kian","family":"Behbakht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicky","family":"Makker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parviz","family":"Hanjani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Zweizig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"II","given":"James J.","family":"Burke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gordon","family":"Downey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly K.","family":"Leslie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Van Hummelen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Birrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gini F.","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2016.02.025_bb0005","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21254","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J. Clin."},{"issue":"20","key":"10.1016\/j.ygyno.2016.02.025_bb0010","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1200\/JCO.2007.10.8431","article-title":"Systemic chemotherapy for uterine carcinoma: metastatic and adjuvant","volume":"25","author":"Fleming","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.ygyno.2016.02.025_bb0015","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.tcb.2015.06.002","article-title":"Regulation of mTORC1 by PI3K signaling","volume":"25","author":"Dibble","year":"2015","journal-title":"Trends Cell Biol."},{"issue":"7","key":"10.1016\/j.ygyno.2016.02.025_bb0020","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/sj.bjc.6605301","article-title":"Somatic mutations are present in all members of the AKT family in endometrial carcinoma","volume":"101","author":"Dutt","year":"2009","journal-title":"Br. J. Cancer"},{"issue":"12","key":"10.1016\/j.ygyno.2016.02.025_bb0025","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.1158\/0008-5472.CAN-11-0549","article-title":"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer","volume":"71","author":"Urick","year":"2011","journal-title":"Cancer Res."},{"issue":"18","key":"10.1016\/j.ygyno.2016.02.025_bb0030","first-page":"3935","article-title":"Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies","volume":"57","author":"Tashiro","year":"1997","journal-title":"Cancer Res."},{"issue":"21","key":"10.1016\/j.ygyno.2016.02.025_bb0035","first-page":"4736","article-title":"PTEN\/MMAC1 mutations in endometrial cancers","volume":"57","author":"Risinger","year":"1997","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.ygyno.2016.02.025_bb0040","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1158\/1078-0432.CCR-10-0540","article-title":"A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas","volume":"17","author":"Rudd","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ygyno.2016.02.025_bb0045","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/sj.bjc.6605109","article-title":"The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas","volume":"101","author":"Shoji","year":"2009","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2016.02.025_bb0050","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Network. TCGAR","year":"2013","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.ygyno.2016.02.025_bb0055","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/bjc.2013.59","article-title":"Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial","volume":"108","author":"Colombo","year":"2013","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2016.02.025_bb0060","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.ygyno.2014.01.015","article-title":"Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study","volume":"132","author":"Fleming","year":"2014","journal-title":"Gynecol. Oncol."},{"issue":"24","key":"10.1016\/j.ygyno.2016.02.025_bb0065","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1200\/JCO.2010.34.1578","article-title":"Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group","volume":"29","author":"Oza","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.02.025_bb0070","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2014.58.8871","article-title":"Randomized phase II trial of ridaforolimus in advanced endometrial carcinoma","author":"Oza","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.ygyno.2016.02.025_bb0075","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1038\/bjc.2013.183","article-title":"Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO","volume":"108","author":"Ray-Coquard","year":"2013","journal-title":"Br. J. Cancer"},{"issue":"8","key":"10.1016\/j.ygyno.2016.02.025_bb0080","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1200\/JCO.2014.58.3401","article-title":"Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma","volume":"33","author":"Slomovitz","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.ygyno.2016.02.025_bb0085","doi-asserted-by":"crossref","first-page":"5415","DOI":"10.1002\/cncr.25515","article-title":"A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma","volume":"116","author":"Slomovitz","year":"2010","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2016.02.025_bb0090","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ygyno.2014.06.033","article-title":"Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer","volume":"135","author":"Tsoref","year":"2014","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2016.02.025_bb0095","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/cncr.28414","article-title":"Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer","volume":"120","author":"Mackay","year":"2014","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ygyno.2016.02.025_bb0100","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/IGC.0000000000000118","article-title":"The search continues: looking for predictive biomarkers for response to mammalian target of rapamycin inhibition in endometrial cancer","volume":"24","author":"Meyer","year":"2014","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"4","key":"10.1016\/j.ygyno.2016.02.025_bb0105","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s11523-012-0242-9","article-title":"Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study","volume":"8","author":"Tredan","year":"2013","journal-title":"Target. Oncol."},{"issue":"15","key":"10.1016\/j.ygyno.2016.02.025_bb0110","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1056\/NEJMoa1403352","article-title":"Response and acquired resistance to everolimus in anaplastic thyroid cancer","volume":"371","author":"Wagle","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"6104","key":"10.1016\/j.ygyno.2016.02.025_bb0115","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1126\/science.1226344","article-title":"Genome sequencing identifies a basis for everolimus sensitivity","volume":"338","author":"Iyer","year":"2012","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.ygyno.2016.02.025_bb0120","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/ng.806","article-title":"A framework for variation discovery and genotyping using next-generation DNA sequencing data","volume":"43","author":"DePristo","year":"2011","journal-title":"Nat. Genet."},{"issue":"3","key":"10.1016\/j.ygyno.2016.02.025_bb0125","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nbt.2514","article-title":"Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples","volume":"31","author":"Cibulskis","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ygyno.2016.02.025_bb0130","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The use of confidence or fiducial limits illustrated in the case of the binomial","volume":"26","author":"Clopper","year":"1934","journal-title":"Biometrika"},{"key":"10.1016\/j.ygyno.2016.02.025_bb0135","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2307\/2347496","article-title":"A method for computing profile-likelihood based confidence intervals","volume":"37","author":"Venzon","year":"1988","journal-title":"Appl. Stat."},{"issue":"7447","key":"10.1016\/j.ygyno.2016.02.025_bb0140","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.ygyno.2016.02.025_bb0145","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/annonc\/mdh316","article-title":"Phase III randomized trial of doxorubicin+cisplatin versus doxorubicin +24-h paclitaxel+filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study","volume":"15","author":"Fleming","year":"2004","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.ygyno.2016.02.025_bb0150","first-page":"3147","article-title":"Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay","volume":"60","author":"Han","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2016.02.025_bb0155","series-title":"Tuberous Sclerosis Complex: Genes, Clinical Features, and Therapeutics","author":"Kwiatkowski","year":"2010"},{"key":"10.1016\/j.ygyno.2016.02.025_bb0160","article-title":"Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial","author":"Bissler","year":"2015","journal-title":"Nephrol. Dial. Transplant."},{"issue":"9861","key":"10.1016\/j.ygyno.2016.02.025_bb0165","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","article-title":"Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"381","author":"Franz","year":"2013","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ygyno.2016.02.025_bb0170","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/humu.22202","article-title":"Functional assessment of TSC2 variants identified in individuals with tuberous sclerosis complex","volume":"34","author":"Hoogeveen-Westerveld","year":"2013","journal-title":"Hum. Mutat."},{"issue":"9","key":"10.1016\/j.ygyno.2016.02.025_bb0175","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.bbadis.2010.06.004","article-title":"Analysis of TSC1 truncations defines regions involved in TSC1 stability, aggregation and interaction","volume":"1802","author":"Hoogeveen-Westerveld","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"issue":"9","key":"10.1016\/j.ygyno.2016.02.025_bb0180","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju245","article-title":"Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma","volume":"106","author":"Liu","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"issue":"2","key":"10.1016\/j.ygyno.2016.02.025_bb0185","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ygyno.2014.06.010","article-title":"Beta-catenin mutations in recurrent FIGO IA grade I endometrioid endometrial cancers","volume":"134","author":"Myers","year":"2014","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825816300488?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825816300488?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T10:05:15Z","timestamp":1668593115000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825816300488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S0090825816300488"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2016.02.025","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology\/Gynecologic Oncology Group study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2016.02.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}